PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
147.50
-5.00 (-3.28%)
At close: 4:24PM IST
Stock chart is not supported by your current browser
Previous Close152.50
Open148.00
Bid147.60 x 128000
Ask147.80 x 209400
Day's Range146.90 - 149.00
52 Week Range143.60 - 276.70
Volume128,178
Avg. Volume305,566
Market Cap216.374M
Beta (3Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
    Zackslast month

    Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Protalix: 3Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...

  • Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know

    Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks4 months ago

    Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
    Simply Wall St.4 months ago

    Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?

    In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...

  • Associated Press4 months ago

    Protalix: 2Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...

  • Associated Press7 months ago

    Protalix: 1Q Earnings Snapshot

    The Carmiel, Israel-based company said it had a loss of 6 cents per share. The drug developer posted revenue of $4.6 million in the period. The company's shares closed at 40 cents. A year ago, they were ...

  • Benzinga9 months ago

    Benzinga Pro's 5 Stock To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. (NASDAQ: ATHX ) stock gained more than ...

  • Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?
    Simply Wall St.9 months ago

    Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?

    Protalix BioTherapeutics Inc’s (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...

  • SmarterAnalyst11 months ago

    Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis

    Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks.  The first 14 patients have completed the study, and four patients are currently in treatment and follow-up.  The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.

  • Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
    Zackslast year

    Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

    Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

  • Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission
    SmarterAnalystlast year

    Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission

    Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race up another close to 7% amid the news of an exciting victory: the Israeli pharma firm's Fabry disease asset PRX-102 gained favor from the European Commission by granting of an Orphan Drug Designation (ODD). Should this orphan drug designation be maintained when the Fabry disease candidate garners approval for marketing in the European Union (EU), this could translate to an advantage of ten years of market exclusivity for Protalix within the EU. For context, the company has designed its PRX-102 asset, or pegunigalsidase alfa, as a plant cell culture expressed, and a chemically modified version of the recombinant alpha-Galactosidase-A protein, aimed to treat Fabry disease that afflicts one person out of every 40,000.